Basilea Pharmaceutica - Revenue upside surprise for 2022
Basilea has announced preliminary, unaudited revenue results for FY22, together with an operational update on its commercial and pipeline assets. Revenues related to the company’s marketed products, Cresemba and Zevtera, were c CHF122m (FY21: CHF131m), exceeding the high end of management guidance by c 17%. Basilea also received revenue in the form of Biomedical Advanced Research and Development Authority reimbursements, proceeds from strategic oncology transactions and other revenue contributions, bringing total revenues for the period to c CHF148m (FY21: CHF148m), which exceed the high end of FY22 guidance by c 21%. In our view, the potential marketing approval of Zevtera in the US will be critical to drive revenue growth. We will update our estimates and valuation after the announcement of Basilea’s full year-end results in February.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.